I wonder why they didn’t announce the first enrollment like they did with Alz.
Are you suggesting that the company may wait to start dosing in the Alz trial until they see preliminary data from PDD?
Also, if they want to piggy back extension trials to gain approvals for Rett and Alz, wouldn’t PDD need to get approved first? And if so, that would mean they would be waiting a good amount of time for that to happen.
I’m not too familiar with the route of gaining approvals through extensions. I know the link you provided multiple times outlined it. If they were trying to do this, wouldn’t it also mean a possible trial redesign which would take much much longer as well?
News 
Market Data 
Discover 
